Treatment
Sintilimab clinical trials
We’re tracking 175 recruiting studies that include Sintilimab, each written for real people, not researchers, below.
Recruiting studies
- NCT06353646Recruiting
XH001 plus immunotherapy and chemotherapy after pancreatic cancer surgery
This trial studies a new treatment called XH001 combined with standard immunotherapy and chemotherapy for people whose pancreatic cancer has been surgically removed. The goal is to see if this combination helps prevent the cancer from coming back.
Beijing, Beijing MunicipalityAges 18–75 - NCT06397222RecruitingPhase 2
Combination therapy for advanced liver cancer
This trial tests a combination of three treatments: an immunotherapy drug (Sintilimab), a targeted therapy (Bevacizumab), and a type of internal radiation (SIRT) for people with intermediate or advanced liver cancer that cannot be surgically removed. The goal is to see if this combination can shrink tumors and improve outcomes.
Guangzhou, GuangdongAges 18–75 - NCT06403878RecruitingPhase 2
Chemo-immunotherapy before surgery for older adults with esophageal cancer
This trial tests whether giving chemotherapy and immunotherapy before surgery is safe and effective for older adults (70+) with a certain type of esophageal cancer. It aims to find a treatment approach that works well for patients who haven't had cancer treatment before.
ChengduAges 70–100 - NCT06405113RecruitingPhase 2
Fecal transplant, chemo, and immunotherapy for advanced stomach cancer
This trial tests a combination of fecal microbiota transplant (FMT), chemotherapy (SOX), and an immunotherapy drug (Sintilimab) as a first treatment for advanced stomach or gastroesophageal junction cancer that cannot be removed by surgery. The goal is to see if this combination can shrink tumors and improve outcomes.
ChangzhouAges 18–80 - NCT06431685RecruitingPhase 1
Brain radiation, immunotherapy, and chemo for lung cancer spread
This trial tests a combination of low-dose radiation to the whole brain, immunotherapy, and chemotherapy given through a lumbar puncture. It is for people with lung cancer that has spread to the lining of the brain and has not responded to standard treatments.
Chengdu, SichuanAges 18–75 - NCT06457477Recruiting
PD-1 antibody and peginterferon for chronic hepatitis B
This trial tests a combination of a PD-1 antibody (a type of immunotherapy) and peginterferon alpha for people with chronic hepatitis B whose virus is already under control but whose surface antigen levels haven't improved much with standard therapy. It aims to see if the combo can help reduce the hepatitis B surface antigen further.
Beijing, Beijing MunicipalityAges 18–65 - NCT06487429RecruitingPhase 2
Short radiation followed by combo therapy for HER2+ stomach cancer
This trial tests a new approach for stomach cancer that has spread to nearby tissues but not to other organs. You would get a short course of radiation, followed by a combination of targeted therapy (Disitamab Vedotin), chemotherapy (S-1), and immunotherapy (Sintilimab) before surgery to shrink the tumor and improve outcomes.
Wuhan, HubeiAges 18–75 - NCT06530251RecruitingPhase 1/Phase 2
AK112 for advanced liver cancer (HCC)
This trial tests a new immunotherapy drug called AK112 for people with advanced liver cancer that hasn't spread to the brain or key blood vessels. It may be an option if you haven't had immunotherapy before and your liver is still working well.
Beijing, Beijing MunicipalityAges 18–75 - NCT06543836RecruitingPhase 2
Targeted therapy plus immunotherapy for advanced colorectal cancer
This trial tests a combination of a targeted therapy pill (TKI) and an immunotherapy (PD-1 inhibitor) for people with advanced colorectal cancer that has stopped responding to standard treatments. It uses a blood test to tailor the treatment, aiming to be more effective with fewer side effects.
Beijing, Beijing MunicipalityAges 18–80 - NCT06561399Recruiting
Triple therapy followed by radiation for liver cancer
This trial tests whether adding targeted radiation therapy can help people with liver cancer that cannot be surgically removed. It is for people who have already received a combination of TACE, lenvatinib, and sintilimab and whose tumors have not grown.
Fuzhou, FujianAges 18–75 - NCT06563869RecruitingPhase 3
Sintilimab with chemo and growth factor before esophageal cancer surgery
This trial tests whether giving the immunotherapy drug sintilimab together with standard chemotherapy and a growth factor injection before surgery can help people with a certain type of esophageal cancer (squamous cell carcinoma) that is still removable. The goal is to improve treatment outcomes before the operation.
Nanjing, JiangsuAges 18–75 - NCT06572813RecruitingPhase 1/Phase 2
Combination therapy for advanced pancreatic cancer
This trial tests whether adding bortezomib and an immunotherapy drug to standard chemotherapy can help people with pancreatic cancer that has spread to other organs. It is for patients who have not had treatment or whose cancer has worsened after gemcitabine-based chemotherapy.
Hangzhou, ZhejiangAges 18–75 - NCT06702683Recruiting
Sintilimab blood levels in advanced stomach cancer
This study looks at how the amount of Sintilimab in your blood relates to how well it works and what side effects you might have. If you have advanced stomach cancer and are planning to get Sintilimab, this trial could help your doctor find the best dose for you.
Nanjing, JiangsuAges 18 years+ - NCT06714903Recruiting
Gut bacteria and immunotherapy for advanced colon cancer
This study looks at how the bacteria in your gut might affect how well immunotherapy works for advanced colorectal cancer that has spread. It aims to find out if certain gut bacteria can help make treatment more effective.
Changchun, JilinAges 35–75 - NCT06759064RecruitingPhase 1/Phase 2
Intraperitoneal Immunotherapy and Bone Drug for Stomach Cancer Belly Fluid
This trial tests a combination of two drugs—one that helps your immune system fight cancer (immune checkpoint inhibitor) and one that strengthens bones (zoledronic acid)—given directly into the belly (intraperitoneal) to control fluid buildup caused by stomach cancer. It may help people with moderate to severe malignant ascites who have not had local belly treatments or immunotherapy recently.
Jinan, ShandongAges 18–75 - NCT06787911RecruitingPhase 2
Donafenib and immunotherapy before surgery for advanced thyroid cancer
This trial tests a combination of two drugs—donafenib (a targeted therapy) and an immunotherapy (anti-PD-1 antibody)—given before surgery for locally advanced differentiated thyroid cancer. The goal is to shrink the tumor to make surgery easier and more complete. If you have this type of thyroid cancer that is hard to remove completely with surgery alone, this study may be an option.
ShanghaiAges 18–80 - NCT06824883RecruitingPhase 2
3-drug combo for untreated NK/T-cell lymphoma
This trial tests a combination of three drugs (sintilimab, pegaspargase, and GemOx) for people with a type of lymphoma called extranodal NK/T-cell lymphoma (ENKTL) that hasn't been treated before. The goal is to see if this combination helps control the disease.
Beijing, Beijing MunicipalityAges 18–75 - NCT06904183RecruitingPhase 2
Study of lenvatinib, sintilimab, and DEB-TACE with or without HAIC for large liver cancer with portal vein tumor thrombus
This trial tests a combination of two drugs (lenvatinib and sintilimab) plus a liver-directed treatment (DEB-TACE) with or without another liver treatment (HAIC) for people with large liver cancer (over 7 cm) that has spread into the main blood vessel of the liver. The goal is to see if adding HAIC helps shrink the cancer more effectively.
Guangzhou, GuangdongAges 18–75 - NCT06979908RecruitingPhase 2
A study of fruquintinib plus immunotherapy for advanced colorectal cancer
This trial tests a combination of three drugs (fruquintinib, a PD-1 inhibitor, and chidamide) for people with a specific type of advanced colorectal cancer that has not responded to at least two prior treatments. The goal is to see if this new combination can shrink tumors or slow the cancer's growth.
Changchun, JilinAges 18–75 - NCT07138755RecruitingPhase 2
PD-1, chemo, and adaptive radiation for stage 3 lung cancer
This study tests if adding an immunotherapy drug (PD-1 inhibitor) to chemotherapy and specially planned radiation works better for stage 3 lung cancer that cannot be surgically removed. It may be an option if you have not had previous treatment for this cancer.
Changsha, HunanAges 18–75 - NCT07157969RecruitingPhase 2
Immunotherapy and anti-VEGF with or without local therapy for liver cancer
This trial tests a combination of immunotherapy (checkpoint inhibitors) and anti-VEGF therapy (which blocks blood vessel growth to tumors) with or without local treatments (like chemoembolization) for advanced liver cancer. It aims to see if the combination works better than current treatments.
BeijingAges 18 years+ - NCT07394387RecruitingPhase 2
HIFU with or without immunotherapy before chemo for triple-negative breast cancer
This trial tests whether adding focused ultrasound (HIFU) and an immunotherapy drug (PD-1 inhibitor) before standard chemotherapy can improve outcomes for women with stage II or III triple-negative breast cancer (TNBC). It aims to find a more effective way to shrink tumors before surgery.
Nanjing, JiangsuAges 18–70 - NCT07422753RecruitingPhase 2
TACE with immunotherapy drugs for advanced liver cancer
This trial tests a combination of TACE (a procedure that blocks blood supply to the tumor) plus three immunotherapy drugs (sintilimab, bevacizumab, ipilimumab) for people with advanced liver cancer that cannot be removed by surgery. The goal is to see if this combination works better than TACE alone.
Hangzhou, ZhejiangAges 18–75 - NCT07455617RecruitingPhase 1
Vaccine for KRAS-mutated advanced solid tumors
This trial tests a new vaccine, ABO2102, for people with advanced solid tumors that have a specific change in the KRAS gene. The vaccine aims to help your immune system fight the cancer.
ShanghaiAges 18 years+
Common questions
- Are there clinical trials studying Sintilimab?
- Yes. Clin2 currently lists 175 recruiting studies that include Sintilimab, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Sintilimab trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Sintilimab an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Sintilimab or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.